WorldHeart to begin rotary VAD trial
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart announced Feb. 15 that it has received approval from the Greek Ministry of Health to begin clinical trials of its second-generation rotary ventricular assist device. WorldHeart acquired the continuous flow pump technology in February 2005 with the purchase of Medquest. The firm says that the VAD initially will be indicated as a bridge to transplant but will eventually be expanded for use as a destination therapy. Thoratec's HeartMate is the only device with FDA approval for permanent support of heart failure patients who are ineligible for transplant...
You may also be interested in...
WorldHeart starts VAD trial
Human implantation of the firm's rotary ventricular assist device (VAD) occurred March 8 in Greece, kicking off a feasibility trial for the device. WorldHeart will seek a bridge-to-transplant indication initially, but eventually aspires to sell the device as a destination therapy. The firm received approval from the Greek Ministry of Health to begin the trial in February (1"The Gray Sheet" Feb. 20, 2006, In Brief)...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.